Model to Determine the Cost-Effectiveness of Screening Psoriasis Patients for Psoriatic Arthritis.

If early therapy with DMARDs delays biologic treatment, implementing screening in patients with psoriasis in Canada is expected to represent a cost savings of $220 million per year and improve the quality of life.